Study in Pediatric Subjects With Epilepsy
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Study in Pediatric Subjects With Epilepsy is a clinical trial[1].
Key Facts
- Study in Pediatric Subjects With Epilepsy is in the country of United States[2].
- Study in Pediatric Subjects With Epilepsy's instance of is recorded as clinical trial[3].
- Study in Pediatric Subjects With Epilepsy's start time is recorded as +2012-07-25T00:00:00Z[4].
- Study in Pediatric Subjects With Epilepsy's end time is recorded as +2013-04-29T00:00:00Z[5].
- Study in Pediatric Subjects With Epilepsy's sponsor is recorded as GSK[6].
- Study in Pediatric Subjects With Epilepsy's main subject is recorded as epilepsy[7].
- Study in Pediatric Subjects With Epilepsy's number of participants is recorded as {'unit': '1', 'amount': '+5'}[8].
- Study in Pediatric Subjects With Epilepsy's title is recorded as Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome[9].
- Study in Pediatric Subjects With Epilepsy's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+12'}[10].
- Study in Pediatric Subjects With Epilepsy's ClinicalTrials.gov ID is recorded as NCT01494584[11].
- Study in Pediatric Subjects With Epilepsy's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+17'}[12].
- Study in Pediatric Subjects With Epilepsy's research intervention is recorded as ezogabine[13].
- Study in Pediatric Subjects With Epilepsy's clinical trial phase is recorded as phase II clinical trial[14].
- Study in Pediatric Subjects With Epilepsy's research site is recorded as GSK[15].
- Study in Pediatric Subjects With Epilepsy's study type is recorded as interventional study[16].